What is MS Phase 3 Study Fingolimod?

Category: Others


Generic name: Fingolimod Clinical Trial

See also: Clinical Trial

NCT01201356 is a single arm, open-label study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis. Other study names are ID#CFTY720D2399 and 2010-020515-37.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 1
Mild 0
None 0

Commonly reported side effects and conditions associated with MS Phase 3 Study Fingolimod

Side effect Patients Percentage
Hair loss 1
Headache on right side of head 1
Itchy back 1
Memory problems 1
Nausea 1
Nerve pain (neuralgia) 1

Show all 8 reported side effects

Why patients stopped taking MS Phase 3 Study Fingolimod

Multiple reasons could be selected

Reason Patients Percentage
Personal research 1
See 1 patient who's stopped using MS Phase 3 Study Fingolimod


Stopped using MS Phase 3 Study Fingolimod

Duration Patients Percentage
1 - 2 years 1
Adherence Evaluations Percentage
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 0
Last updated:
There are no evaluations for MS Phase 3 Study Fingolimod.